harrysnel schreef op 9 januari 2015 11:15:
ABBVIE ISSUES STRONG OUTLOOK FOR 2015
- EXPECTS ADJUSTED EARNINGS PER SHARE OF $4.25 TO $4.45 (GAAP EPS OF $3.99 TO $4.19); GUIDANCE TO BE FURTHER REFINED AS HCV LAUNCH PROGRESSES
- GUIDANCE MIDPOINT REFLECTS ADJUSTED EPS GROWTH OF MORE THAN 30 PERCENT FROM ABBVIE'S PREVIOUSLY COMMUNICATED 2014 GUIDANCE RANGE
Jan 8, 2015
NORTH CHICAGO, Ill., Jan. 8, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) today issued earnings-per-share guidance for the full-year 2015.
....
In 2015, the company expects a number of important data and regulatory milestones, as well as clinical program advancements, including:
Regulatory approval of HCV regimen in Europe
HCV regulatory submission in Japan
ABT-199 data in relapse/refractory CLL patients with 17p deletion
Zinbryta (daclizumab) regulatory submissions in U.S. and Europe
Elagolix Phase 3 data in endometriosis and Phase 2b data in uterine fibroids
Phase 2b data from next-generation HCV program
U.S. regulatory approval of Duopa for advanced Parkinson's disease
Mid-stage data from selective JAK-1 programsElotuzumab Phase 3 data in multiple myeloma
Mid-stage data from a number of oncology programs including veliparib, ABT-414 and ABT-199 in other indications
HUMIRA hidradenitis suppurativa regulatory decisions
HUMIRA uveitis pivotal data and regulatory submissions
....
abbvie.mediaroom.com/2015-01-08-AbbVi...Wat zou de bedoeling van Abbvie zijn om deze outlook nu al voor 2015 te geven?
Verwachtte men een positief effect op het aandeel?
Mocht Abbvie een bedrijf overnemen, b.v. Galapagos en daarvoor aandelen willen gebruiken dan is een hoge koers van het aandeel toch mooi
meegenomen. Of denk ik verkeerd?
Met vr.groet Jeroen.